Merit Medical Systems (MMSI)
(Delayed Data from NSDQ)
$88.74 USD
+4.62 (5.49%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $88.71 -0.03 (-0.03%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$88.74 USD
+4.62 (5.49%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $88.71 -0.03 (-0.03%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth C Momentum C VGM
Zacks News
PDCO vs. MMSI: Which Stock Is the Better Value Option?
by Zacks Equity Research
PDCO vs. MMSI: Which Stock Is the Better Value Option?
Ensign Group (ENSG) Q3 Earnings Beat on Occupancy, Stock Up 2.4%
by Zacks Equity Research
Ensign Group's (ENSG) third-quarter results benefit on solid segmental contribution and occupancy strength. Management currently expects adjusted EPS to be within $4.73-$4.79 for 2023.
Merit Medical (MMSI) Q3 Earnings Top Estimates, FY23 View Revised
by Zacks Equity Research
Merit Medical (MMSI) benefits from revenue growth in both segments and all product categories within its Cardiovascular unit in the third quarter.
Merit Medical (MMSI) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
Although the revenue and EPS for Merit Medical (MMSI) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Merit Medical (MMSI) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Merit Medical (MMSI) delivered earnings and revenue surprises of 15.38% and 2.93%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
MedTech Stocks to Watch for Earnings on Oct 26: WST, DXCM & More
by Debanjana Dey
MedTech companies' Q3 results are likely to reflect strength in customer demand. Let's see how WST, DXCM, MMSI and ITGR are placed ahead of their earnings releases.
Merit Medical's (MMSI) New Launch to Expand Its Product Suite
by Zacks Equity Research
Merit Medical's (MMSI) latest addition to its Vascular portfolio is expected to significantly improve patient outcomes.
HSIC vs. MMSI: Which Stock Is the Better Value Option?
by Zacks Equity Research
HSIC vs. MMSI: Which Stock Is the Better Value Option?
Here's Why You Should Add McKesson (MCK) to Your Portfolio
by Zacks Equity Research
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
3 Reasons to Add Merit Medical (MMSI) Stock to Your Portfolio
by Zacks Equity Research
Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Merit Medical's (MMSI) Aspira Bottle to Boost At-Home Services
by Zacks Equity Research
Merit Medical (MMSI) launches Aspira Bottle, complementing its Aspira Drainage System, that can provide compassionate home treatment option for critical cancer and other patients.
Reasons to Retain Merit Medical (MMSI) Stock in Your Portfolio
by Zacks Equity Research
Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.
PDCO or MMSI: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PDCO vs. MMSI: Which Stock Is the Better Value Option?
Merit Medical (MMSI) Completes Enrollment in WRAPSODY Study
by Zacks Equity Research
Merit Medical (MMSI) is evaluating its device for treating stenosis/occlusion, WRAPSODY, in a pivotal study on patients undergoing hemodialysis. Primary data from the study is expected after six months.
Merit Medical (MMSI) Q2 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Merit Medical (MMSI) benefits from revenue growth in both segments and all product categories within its Cardiovascular unit in the second quarter.
Merit Medical (MMSI) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Merit Medical (MMSI) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Merit Medical (MMSI) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Merit Medical (MMSI) delivered earnings and revenue surprises of 8% and 3.16%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Here's Why You Should Retain Merit Medical (MMSI) Stock for Now
by Zacks Equity Research
Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.
PDCO or MMSI: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PDCO vs. MMSI: Which Stock Is the Better Value Option?
Amedisys (AMED) to Advance Value-Based Care With Optum Merger
by Zacks Equity Research
Amedisys' (AMED) combination with Optum brings together two organizations committed to offering patients and their families compassionate, value-based comprehensive care.
Here's Why You Should Retain CVS Health (CVS) Stock for Now
by Zacks Equity Research
Investors are optimistic about CVS Health (CVS) backed by the acquisition of Oak Street Health, which broadens its value-based primary care platform.
Here's Why Investors Should Retain Abbott (ABT) Stock Now
by Zacks Equity Research
Investors are optimistic about Abbott (ABT) on continued growth in Diabetes business and upbeat guidance.
Inspire Medical (INSP) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about Inspire Medical's (INSP) global presence.